Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

RXRuirong Xu

Discussion

Loading...

Member takes

Overview

Randomized clinical trial demonstrated that chidamide improves efficacy and safety in patients with refractory ITP, suggesting a viable treatment option.

Key Points

  • The study aims to evaluate the efficacy and safety of chidamide in adult patients with refractory primary immune thrombocytopenia.
  • Prospective, multicenter, open-label, randomized clinical trial
  • Participants received chidamide at dosages of 2.5 mg or 5 mg twice per week
  • Primary endpoint was overall response rate at week 12, with secondary endpoints including sustained response and quality of life assessments.
  • The 5 mg group had a significantly higher overall response rate at week 12 (43.3%) compared to the 2.5 mg group (16.1%), p=0.0262.
  • The 6-month sustained response rate was significantly higher in the 5 mg group (33.3%) versus the 2.5 mg group (3.2%), p=0.0026.
  • Responders in the 5 mg group experienced a longer median duration of response (48 weeks) compared to the 2.5 mg group (8 weeks), p=0.0180.

Cite This Study

Ruirong Xu (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dea3https://doi.org/10.1182/blood-2025-3043
View Full Paper
Ask AI
Bookmark
Share